)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Corvus Pharmaceuticals (CRVS) investor relations material
Corvus Pharmaceuticals Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary7 Aug, 2025
Executive summary
Socolitinib/soquelitinib advanced in atopic dermatitis (Phase 1, extension cohort enrolling, Phase 2 to start by year-end) and relapsed/refractory T cell lymphomas (Phase 3 enrolling), with strong efficacy and safety data and FDA Fast Track/Orphan Drug status.
Additional programs include ongoing trials in renal cell cancer, autoimmune lymphoproliferative syndrome, and NSCLC, with ciforadenant and mupadolimab in clinical development.
Net income of $7.2M for the six months ended June 30, 2025, driven by a $27.1M non-operating gain from warrant liability revaluation; Q2 2025 net loss was $8.0M.
Cash, cash equivalents, and marketable securities totaled $74.4M as of June 30, 2025, supporting operations into Q4 2026.
Preclinical soquelitinib data in systemic sclerosis recognized as a top 10 abstract at EULAR 2025.
Financial highlights
Q2 2025 net loss was $8.0M, compared to $4.3M in Q2 2024; six-month net income was $7.2M, mainly due to warrant liability revaluation.
R&D expenses for Q2 2025 were $7.9M, up from $4.1M year-over-year, mainly due to increased clinical and manufacturing costs.
Operating expenses rose to $10.3M in Q2 2025 from $5.9M in Q2 2024.
Cash position increased to $74.4M as of June 30, 2025, up from $52.0M at year-end 2024, bolstered by warrant exercises.
Non-cash loss from Angel Pharmaceuticals was $0.4M for Q2 2025.
Outlook and guidance
Cash runway expected to fund operations into Q4 2026; additional capital may be needed for future trials.
Data from extension cohort of the Phase 1 atopic dermatitis trial anticipated in Q4 2025; Phase 2 trial to start by year-end.
Guidance for interim data from the Phase 3 PTCL trial remains late 2026.
Angel Pharmaceuticals to initiate a Phase 1b/2 trial in China for atopic dermatitis.
How does Phase II AD design impact enrollment?
What is the strategy for soquelitinib next indications?
What are the next steps for Cifo after ESMO?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Corvus Pharmaceuticals earnings date
Q3 202511 Nov, 2025
Next Corvus Pharmaceuticals earnings date
Q3 202511 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Corvus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing immune-oncology therapies for the treatment of cancer and immune-related diseases. The company’s pipeline includes drug candidates that target key immune pathways to enhance the body’s immune response against cancer cells. The company is headquartered in Burlingame, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage